NCT02211222Approved For Marketing不适用
An Open-Label, Randomized, Multicenter, Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Eisai Inc.
研究概览
简要总结
This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset HypophosphatasiaHypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme.With deficiency of Tissue-nonspecific alkaline phosphatase, there is a buildup of extracellular inorganic pyrophosphate, which inhibits mineralization of bone matrix.MedDRA version: 20.0Level: PTClassification code 10049933Term: HypophosphatasiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003131-35-DEAlexion Pharma GmbH36
进行中（未招募）
不适用
PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.EUCTR2013-000432-10-ITDUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVO154
进行中（未招募）
不适用
A Multicenter, Open-Label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin in comparison with Paclitaxel and Carboplatin against Anaplastic Thyroid Carcinoma - NAEUCTR2007-002846-38-BGOXiGENE, Inc.180
Unknown
2 期
A Clinical study to evaluate the effect of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma patients.CTRI/2009/091/000057Oxigene Inc180
招募中
Unknown
An open-label, randomized, multicentre, phase ? trial of Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancersNeoplasmsKCT0008772ational Cancer Center98